VolitionRx (NYSE:VNRX) Now Covered by StockNews.com

Analysts at StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a research report issued to clients and investors on Thursday. The firm set a “sell” rating on the stock.

Separately, Benchmark reissued a “hold” rating on shares of VolitionRx in a report on Friday, August 16th.

VolitionRx Stock Performance

Shares of NYSE:VNRX opened at $0.69 on Thursday. The company’s fifty day moving average is $0.64 and its two-hundred day moving average is $0.69. VolitionRx has a 1-year low of $0.43 and a 1-year high of $1.23. The stock has a market capitalization of $63.83 million, a price-to-earnings ratio of -1.51 and a beta of 1.12.

VolitionRx (NYSE:VNRX) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.01. The business had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.34 million. Sell-side analysts expect that VolitionRx will post -0.31 EPS for the current fiscal year.

Insider Activity at VolitionRx

In other news, Director Guy Archibald Innes acquired 150,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The shares were purchased at an average cost of $0.67 per share, for a total transaction of $100,500.00. Following the transaction, the director now directly owns 406,683 shares in the company, valued at approximately $272,477.61. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 12.80% of the stock is currently owned by insiders.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.